Using clinically-assessed risk factors, researchers developed and validated a model for incident first-primary cutaneous melanoma.
Publications
The impact of targeted therapies and immunotherapy in melanoma brain metastases: A systematic review and meta-analysis
Researchers sought to elucidate the activity and efficacy of targeted therapies (TT), combination immunotherapy (CMI), and monoimmunotherapy (MI) in combination with radiotherapy or not, which are commonly used in patients with melanoma brain metastases.
Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non–small cell lung cancer treated with nivolumab
In this secondary analysis of phase 1 CA209-003 trial, researchers examined 270 patients with advanced melanoma, renal cell carcinoma (RCC), or non–small cell lung cancer (NSCLC) to determine 5-year survival associated with nivolumab treatment in these patients, as well as to identify factors related to 5-year survival.
Bempegaldesleukin Plus Nivolumab Granted Breakthrough Designation in Melanoma by the FDA
The combination of bempegaldesleukin (NKTR-214) and nivolumab (Opdivo) was granted a breakthrough therapy designation by the FDA for the treatment of patients with previously untreated unresectable or metastatic melanoma.